A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?
Villani V, Fabi A, Tanzilli A, Pasqualetti F, Lombardi G, Vidiri A, Gonnelli A, Molinari A, Cantarella M, Bellu L, Terrenato I, Carosi M, Maschio M, Telera SM, Carapella CM, Cognetti F, Paiar F, Zagonel V, Pace A.
Villani V, et al. Among authors: lombardi g.
Future Oncol. 2019 May;15(15):1717-1727. doi: 10.2217/fon-2018-0826. Epub 2019 Apr 12.
Future Oncol. 2019.
PMID: 30977687